{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:50:24Z","timestamp":1783813824904,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.leukres.2019.106272","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T13:29:17Z","timestamp":1573910957000},"page":"106272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-\u00adpolycythemia vera\/essential thrombocythemia myelofibrosis (post-\u00adPV\/ET MF)"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"J.","family":"Mascarenhas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6175","authenticated-orcid":false,"given":"B.K.","family":"Marcellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Houldsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Najfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"El Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.leukres.2019.106272_bib0005","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.leukres.2019.106272_bib0010","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2019.106272_bib0015","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.leukres.2019.106272_bib0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2019.106272_bib0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2019.106272_bib0035","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","article-title":"A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis","volume":"121","author":"Mascarenhas","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106272_bib0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.biochem.71.110601.135400","article-title":"ATP-dependent nucleosome remodeling","volume":"71","author":"Becker","year":"2002","journal-title":"Annu. Rev. Biochem."},{"issue":"11","key":"10.1016\/j.leukres.2019.106272_bib0045","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e31803c72ba","article-title":"Histone deacetylase inhibitors: biology and mechanism of action","volume":"13","author":"Mehnert","year":"2007","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.leukres.2019.106272_bib0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.leukres.2019.106272_bib0065","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106272_bib0070","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1074\/jbc.M509901200","article-title":"The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons","volume":"281","author":"Shang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.12220","article-title":"A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera\/essential thrombocythaemia myelofibrosis (post-PV\/ET MF)","volume":"161","author":"Mascarenhas","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.106272_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.11.015","article-title":"A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera\/essential thrombocythemia myelofibrosis (post-PV\/ET MF)","volume":"53","author":"Mascarenhas","year":"2017","journal-title":"Leuk. Res."},{"issue":"24","key":"10.1016\/j.leukres.2019.106272_bib0085","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.leukres.2019.106272_bib0090","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.leukres.2019.106272_bib0100","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.leukres.2019.106272_bib0105","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.leukres.2019.106272_bib0110","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.leukres.2010.07.015","article-title":"What are RBC-transfusion-dependence and -independence?","volume":"35","author":"Gale","year":"2011","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.leukres.2019.106272_bib0120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.leukres.2019.106272_bib0125","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in Cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.leukres.2019.106272_bib0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13148-011-0050-6","article-title":"Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies","volume":"2","author":"Mascarenhas","year":"2011","journal-title":"Clin. Epigenetics"},{"issue":"12","key":"10.1016\/j.leukres.2019.106272_bib0135","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190802527699","article-title":"Enhanced histone deacetylase enzyme activity in primary myelofibrosis","volume":"49","author":"Wang","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2019.106272_bib0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428194.2011.597905","article-title":"Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"53","author":"Skov","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2019.106272_bib0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001622-200311000-00003","article-title":"Heat shock protein 90","volume":"15","author":"Neckers","year":"2003","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2019.106272_bib0150","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"DeAngelo","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.leukres.2019.106272_bib0155","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood.V122.21.4045.4045","article-title":"A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (PMF), post\u2013polycythemia Vera mf (PPV-MF), or post\u2013essential thrombocythemia MF (PET-MF): identification of the recommended phase 2 dose","volume":"122","author":"Vincen t Ribrag","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2019.106272_bib0160","article-title":"A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis","volume":"32","author":"Florian Heidel","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106272_bib0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.106272_bib0170","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Quintas-Cardama","year":"2012","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2019.106272_bib0175","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/10428194.2018.1543876","article-title":"A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis","volume":"60","author":"Bose","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"13","key":"10.1016\/j.leukres.2019.106272_bib0180","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","article-title":"Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2019.106272_bib0185","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2019.106272_bib0190","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north american intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2019.106272_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143897","article-title":"The bone marrow-mediated protection of myeloproliferative neoplastic cells to vorinostat and ruxolitinib relies on the activation of JNK and PI3K signalling pathways","volume":"10","author":"Cardoso","year":"2015","journal-title":"PLoS One"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:54Z","timestamp":1758934794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619307179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"alternative-id":["S0145212619307179"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106272","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-\u00adpolycythemia vera\/essential thrombocythemia myelofibrosis (post-\u00adPV\/ET MF)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106272"}}